Drug Profile
Research programme: ras-selective modified adenoviruses - Oncolytics Biotech
Alternative Names: Ras-selective modified adenoviruses - Oncolytics BiotechLatest Information Update: 14 May 2011
Price :
$50
*
At a glance
- Originator Oncolytics Biotech; The Catalan Institute of Oncology
- Developer Oncolytics Biotech
- Class Viruses
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 24 Oct 2008 Pharmacodynamic data from a preclinical study in Malignant melanoma presented at the 20th-EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
- 29 Sep 2003 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
- 05 Aug 2003 Preclinical trials in Cancer in Canada (unspecified route)